- Cash and equivalents totaled $23.5 million in the U.S. and $142.1 million consolidated including China balances.
- FibroGen reported total revenue of $1.3 million in Q2 2025, up from $1 million in Q2 2024.
- Net loss from continuing operations was $13.7 million or $3.38 per share, improved from a $47.1 million loss or $11.79 per share in Q2 2024.
- Operating costs and expenses decreased by 72% year-over-year to $13.4 million in Q2 2025.
- R&D expenses fell 82% to $5.9 million, and SG&A expenses decreased 53% to $7.1 million compared to Q2 2024.
- The company was cash flow positive in Q2 2025, generating $13.7 million on a consolidated basis.
Related items and other data are not available for this feed item.
Dafinchi